CA2515095A1 - Schema posologique pour nelfinavir - Google Patents

Schema posologique pour nelfinavir Download PDF

Info

Publication number: CA2515095A1
Authority: CA; Canada
Prior art keywords: nelfinavir; fat; food; administration; auc
Prior art date: 2003-02-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002515095A

Other languages

English (en)

Inventor

Carolyn Petersen

Edward Fu Ceayong Pun

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Inc

Original Assignee

Pfizer Inc.

Carolyn Petersen

Edward Fu Ceayong Pun

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-10

Filing date

2004-01-29

Publication date

2004-08-19

2004-01-29 Application filed by Pfizer Inc., Carolyn Petersen, Edward Fu Ceayong Pun filed Critical Pfizer Inc.

2004-08-19 Publication of CA2515095A1 publication Critical patent/CA2515095A1/fr

Status Abandoned legal-status Critical Current

Links

QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 title claims abstract description 201
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 title claims abstract description 195
229960000884 nelfinavir Drugs 0.000 title claims abstract description 195
235000013305 food Nutrition 0.000 claims abstract description 57
238000000034 method Methods 0.000 claims abstract description 45
241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 35
241000124008 Mammalia Species 0.000 claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
238000011282 treatment Methods 0.000 claims description 30
239000000203 mixture Substances 0.000 claims description 9
229940002612 prodrug Drugs 0.000 claims description 5
239000000651 prodrug Substances 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
239000012453 solvate Substances 0.000 claims description 5
230000001225 therapeutic effect Effects 0.000 claims description 5
235000019197 fats Nutrition 0.000 description 118
235000012054 meals Nutrition 0.000 description 108
230000036470 plasma concentration Effects 0.000 description 27
238000012360 testing method Methods 0.000 description 26
235000004213 low-fat Nutrition 0.000 description 22
230000000694 effects Effects 0.000 description 19
235000019625 fat content Nutrition 0.000 description 19
239000003826 tablet Substances 0.000 description 17
235000021152 breakfast Nutrition 0.000 description 16
238000011156 evaluation Methods 0.000 description 13
235000012631 food intake Nutrition 0.000 description 10
238000004458 analytical method Methods 0.000 description 8
239000008280 blood Substances 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000003814 drug Substances 0.000 description 8
230000037406 food intake Effects 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
238000000540 analysis of variance Methods 0.000 description 7
229940079593 drug Drugs 0.000 description 7
230000009246 food effect Effects 0.000 description 7
235000021193 standardized breakfast Nutrition 0.000 description 7
239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
108010010369 HIV Protease Proteins 0.000 description 5
235000014121 butter Nutrition 0.000 description 5
239000012530 fluid Substances 0.000 description 5
NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 5
XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 4
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 4
WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 4
235000021471 food effect Nutrition 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
235000013336 milk Nutrition 0.000 description 4
239000008267 milk Substances 0.000 description 4
210000004080 milk Anatomy 0.000 description 4
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 4
-1 ACT Chemical compound 0.000 description 3
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
229960001830 amprenavir Drugs 0.000 description 3
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 3
235000019577 caloric intake Nutrition 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 3
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 3
XWESXZZECGOXDQ-UHFFFAOYSA-N n-tert-butylhydroxylamine Chemical class CC(C)(C)NO XWESXZZECGOXDQ-UHFFFAOYSA-N 0.000 description 3
238000003860 storage Methods 0.000 description 3
235000013616 tea Nutrition 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
240000000560 Citrus x paradisi Species 0.000 description 2
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
229940122440 HIV protease inhibitor Drugs 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
244000269722 Thea sinensis Species 0.000 description 2
WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
239000012491 analyte Substances 0.000 description 2
235000008429 bread Nutrition 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
229960003804 efavirenz Drugs 0.000 description 2
235000020937 fasting conditions Nutrition 0.000 description 2
239000004030 hiv protease inhibitor Substances 0.000 description 2
229960001936 indinavir Drugs 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
229960004525 lopinavir Drugs 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002483 medication Methods 0.000 description 2
229940025676 nelfinavir 250 mg Drugs 0.000 description 2
NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 description 2
229960005230 nelfinavir mesylate Drugs 0.000 description 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
238000009597 pregnancy test Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
229960000311 ritonavir Drugs 0.000 description 2
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
238000005070 sampling Methods 0.000 description 2
229960001852 saquinavir Drugs 0.000 description 2
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
238000000528 statistical test Methods 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
229940023080 viracept Drugs 0.000 description 2
235000013618 yogurt Nutrition 0.000 description 2
JTEGQNOMFQHVDC-RQJHMYQMSA-N 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1 JTEGQNOMFQHVDC-RQJHMYQMSA-N 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010048474 Fat redistribution Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
241000700605 Viruses Species 0.000 description 1
GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 description 1
229960004748 abacavir Drugs 0.000 description 1
MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 1
229960001997 adefovir Drugs 0.000 description 1
229960003205 adefovir dipivoxil Drugs 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
235000015241 bacon Nutrition 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000015155 buttermilk Nutrition 0.000 description 1
MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
229940014461 combivir Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940088900 crixivan Drugs 0.000 description 1
238000011157 data evaluation Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
229960005319 delavirdine Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229960002656 didanosine Drugs 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229940072253 epivir Drugs 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
235000013410 fast food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
235000021153 full breakfast Nutrition 0.000 description 1
229940125777 fusion inhibitor Drugs 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
229940096120 hydrea Drugs 0.000 description 1
229960001330 hydroxycarbamide Drugs 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
235000015094 jam Nutrition 0.000 description 1
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004066 metabolic change Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
235000012015 potatoes Nutrition 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
229940063627 rescriptor Drugs 0.000 description 1
229940064914 retrovir Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000004088 simulation Methods 0.000 description 1
235000011888 snacks Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229960001203 stavudine Drugs 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229940054565 sustiva Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229940098802 viramune Drugs 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1
229940052255 ziagen Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Organic Chemistry (AREA)
Mycology (AREA)
Nutrition Science (AREA)
Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002515095A 2003-02-10 2004-01-29 Schema posologique pour nelfinavir Abandoned CA2515095A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US44644403P	2003-02-10	2003-02-10
US60/446,444		2003-02-10
US52425803P	2003-11-21	2003-11-21
US60/524,258		2003-11-21
PCT/IB2004/000313 WO2004069251A1 (fr)	2003-02-10	2004-01-29	Schema posologique pour nelfinavir

Publications (1)

Publication Number	Publication Date
CA2515095A1 true CA2515095A1 (fr)	2004-08-19

Family

ID=32853430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002515095A Abandoned CA2515095A1 (fr)	2003-02-10	2004-01-29	Schema posologique pour nelfinavir

Country Status (13)

Country	Link
EP (1)	EP1605942A1 (fr)
JP (1)	JP2006517221A (fr)
AR (1)	AR043133A1 (fr)
BR (1)	BRPI0407174A (fr)
CA (1)	CA2515095A1 (fr)
CL (1)	CL2004000202A1 (fr)
MX (1)	MXPA05008425A (fr)
NL (1)	NL1025449C2 (fr)
PA (1)	PA8595301A1 (fr)
PE (1)	PE20040948A1 (fr)
TW (1)	TW200423922A (fr)
UY (1)	UY28183A1 (fr)
WO (1)	WO2004069251A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7157455B2 (en)	2003-02-10	2007-01-02	Hoffmann-La Roche Inc.	4-Aminopyrimidine-5-one derivatives

2004
- 2004-01-29 JP JP2006502411A patent/JP2006517221A/ja active Pending
- 2004-01-29 MX MXPA05008425A patent/MXPA05008425A/es unknown
- 2004-01-29 WO PCT/IB2004/000313 patent/WO2004069251A1/fr not_active Application Discontinuation
- 2004-01-29 CA CA002515095A patent/CA2515095A1/fr not_active Abandoned
- 2004-01-29 BR BR0407174-3A patent/BRPI0407174A/pt not_active IP Right Cessation
- 2004-01-29 EP EP04706250A patent/EP1605942A1/fr not_active Withdrawn
- 2004-02-05 CL CL200400202A patent/CL2004000202A1/es unknown
- 2004-02-09 TW TW093102921A patent/TW200423922A/zh unknown
- 2004-02-09 AR ARP040100399A patent/AR043133A1/es unknown
- 2004-02-09 PE PE2004000146A patent/PE20040948A1/es not_active Application Discontinuation
- 2004-02-09 PA PA20048595301A patent/PA8595301A1/es unknown
- 2004-02-10 UY UY28183A patent/UY28183A1/es not_active Application Discontinuation
- 2004-02-10 NL NL1025449A patent/NL1025449C2/nl not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP1605942A1 (fr)	2005-12-21
AR043133A1 (es)	2005-07-20
CL2004000202A1 (es)	2005-03-18
NL1025449A1 (nl)	2004-08-12
UY28183A1 (es)	2004-09-30
WO2004069251A1 (fr)	2004-08-19
PA8595301A1 (es)	2005-08-04
JP2006517221A (ja)	2006-07-20
TW200423922A (en)	2004-11-16
PE20040948A1 (es)	2004-12-27
NL1025449C2 (nl)	2005-03-15
MXPA05008425A (es)	2005-10-19
BRPI0407174A (pt)	2006-02-07

Legal Events

Date	Code	Title	Description
2005-08-04	EEER	Examination request
2008-01-29	FZDE	Dead

Publication	Publication Date	Title
Shabert et al.	1999	Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial
Fujioka et al.	2006	The effects of grapefruit on weight and insulin resistance: relationship to the metabolic syndrome
Falcoz et al.	2002	Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers
JP2017506651A (ja)	2017-03-09	脂肪肝の低減または予防のための組成物および方法
Chittick et al.	1999	Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food
Karim et al.	1985	Food‐induced changes in theophylline absorption from controlled‐release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption
Beavers et al.	2015	Effect of protein source during weight loss on body composition, cardiometabolic risk and physical performance in abdominally obese, older adults: a pilot feeding study
EA029765B1 (ru)	2018-05-31	Способ снижения массы тела и/или количества жира в организме или профилактики увеличения массы тела и/или количества жира в организме или ускорения снижения массы тела и/или количества жира в организме у пациента с диагнозом избыточной массы тела или ожирения с помощью эмпаглифлозина и лекарственного средства от ожирения
TW202015667A (zh)	2020-05-01	治療血色素異常及地中海型貧血之組合物及方法
US20190358240A1 (en)	2019-11-28	Hiv treatment formulation of atazanavir and cobicistat
Tanumihardjo et al.	1994	Comparison of vitamin A status assessment techniques in children from two Indonesian villages
Christiansen et al.	2015	Evaluation of the use of Göttingen minipigs to predict food effects on the oral absorption of drugs in humans
Schöller‐Gyüre et al.	2008	Effects of different meal compositions and fasted state on the oral bioavailability of etravirine
Yuen et al.	2001	Abacavir/Lamivudine/Zidovudme as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption
Türck et al.	1995	Effect of food on the pharmacokinetics of meloxicam after oral administration
Mori et al.	2012	Cutaneous adverse reactions to amoxicillin-clavulanic acid suspension in children: the role of sodium benzoate
US20230181599A1 (en)	2023-06-15	Progestogen formulations and uses thereof
US11980684B2 (en)	2024-05-14	Allergenic protein formulations for immunotherapy
JP2015504088A (ja)	2015-02-05	肝疾患の治療
Boyd et al.	2003	Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects
Faraji et al.	2022	Brewed chicory leaf consumption has unexpected side effects along beneficial effects on liver enzymes in non-alcoholic fatty liver disease patients
Hoody et al.	2003	Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children
CA2515095A1 (fr)	2004-08-19	Schema posologique pour nelfinavir
McLachlan et al.	2006	Meals and medicines
US20040186066A1 (en)	2004-09-23	Method of treatment with nelfinavir